Original Research
Published on 29 Apr 2024
The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses
in Drug Metabolism and Transport
- 2,000 views
- 2 citations